Patents by Inventor Tays HERNÁNDEZ GARCíA

Tays HERNÁNDEZ GARCíA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion proteins composed of an interleukin-2 mutein and type I interferon
    Patent number: 11926654
    Abstract: The present invention describes fusion proteins based on cytokines, called bi-cytokines (BC), specifically formed by the binding of an IL2 agonist mutein with a type I interferon (IFN), linked by an Fc region of a mutant human IgG1 and a connector peptide. The combination of an IL2 agonist mutein and a type I IFN in the structure of the bi-cytokines gives surprising immunoregulatory properties to these molecules and a superior therapeutic effect than that of parental cytokines, or their combination, which makes them attractive and novel molecules for the treatment of cancer. Pharmaceutical compositions comprising as an active ingredient the fusion proteins object of this patent are also described.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: March 12, 2024
    Assignee: CENTRO DE INMUNOLOGIA MOLECULAR
    Inventors: Tays Hernández García, Maura Lisett Rábade Chediak, Kalet León Monzón, Circe Mesa Pardillo, Luis Enrique Fernández Molina, Giselle Hevia Hernández
  • Fusion Proteins Composed of an Interleukin-2 Mutein and Type I Interferon
    Publication number: 20210238246
    Abstract: The present invention describes fusion proteins based on cytokines, called bi-cytokines (BC), specifically formed by the binding of an IL2 agonist mutein with a type I interferon (IFN), linked by an Fc region of a mutant human IgG1 and a connector peptide. The combination of an IL2 agonist mutein and a type I IFN in the structure of the bi-cytokines gives surprising immunoregulatory properties to these molecules and a superior therapeutic effect than that of parental cytokines, or their combination, which makes them attractive and novel molecules for the treatment of cancer. Pharmaceutical compositions comprising as an active ingredient the fusion proteins object of this patent are also described.
    Type: Application
    Filed: March 5, 2019
    Publication date: August 5, 2021
    Applicant: Centro de Inmunologia Molecular
    Inventors: Tays HERNÁNDEZ GARCíA, Maura Lisett RÁBADE CHEDIAK, Kalet LEÓN MONZÓN, Circe MESA PARDILLO, Luis Enrique FERNÁNDEZ MOLINA, Giselle HEVIA HERNÁNDEZ